| abstract |
The present invention relates to a combination vaccine against measles and human papillomavirus (HPV). In particular, the invention relates to HPV-derived single or several antigens, preferably type 16 HPV, and optionally type 18, type 6 and type 11 HPV major capsid antigen L1, trace capsid antigen L2, early gene E6. Recombinant measles virus vector comprising a heterologous nucleic acid encoding an oncoprotein and an early gene E7 oncoprotein. In a first embodiment, an HPV antigen, preferably L1 and / or L2, is expressed so as to induce a strong and persistent immune response in a mammal, preferably a human and protect against HPV and MV infections A prophylactic vaccine is made. In another embodiment, E6 and E7 proteins, and optionally L1 so that the strong immune response induced resolves persistent HPV infection (including HPV-induced cervical cancer) in the early or late stages And a therapeutic vaccine expressing L2 is made. In a preferred embodiment, the combination vaccine is easy to manufacture on a large scale and can be distributed at low cost. |